What Levosimendan Richet Treats: Main Uses and Benefits

Levosimendan Richet is used to provide supportive treatment for patients experiencing severe heart failure where the heart's pumping action has significantly worsened. The medication is generally applied in acute clinical settings when symptoms are profound and immediate, often when additional symptomatic support is needed. It is commonly used for the short-term treatment of severe heart failure.

Easing Distressing Symptoms of Congestion

The primary goal is to assist with maintaining comfort by addressing the distressing symptoms associated with cardiac decompensation, which include severe shortness of breath and fluid retention (edema). By supporting the heart's function, the treatment may assist with maintaining comfort during periods of heightened symptoms and supports patients during difficult episodes by easing distress. The treatment is also relevant for helping to alleviate the associated extreme fatigue and general physical weakness.

---

Quick Fact: Relief for Congestion Symptoms

The treatment is relevant for managing symptom clusters that may become intense or disruptive, such as those related to circulatory strain, and contributes to easing the overall symptom load by promoting better blood flow.

Regulatory References

1. European Medicines Agency Summary of Product Characteristics for Simdax

Who Can and Cannot Use Levosimendan Richet?

Population eligibility for Levosimendan Richet is strictly defined by regulatory documents, distinguishing between acceptable use, conditional use, and absolute contraindications. The standard licensed population is adult patients.

Contraindications (Must Not Use)

The medicine is absolutely prohibited in patients with pre-existing conditions that include:

• Severe renal impairment (creatinine clearance less than 30 ml/min) or severe hepatic impairment.
• Severe hypotension (very low blood pressure) or severe tachycardia (abnormally fast heart rate).
• Significant mechanical obstructions affecting heart function.
• Hypersensitivity to levosimendan.

Age and Reproductive Limitations

Population	Regulatory Status
Children/Adolescents (Under 18)	Not Recommended (Prohibited due to very limited experience).
Elderly Patients	Use is permitted; no dose adjustment is required.
Pregnancy	Conditional Use (Only if benefits outweigh risks to the fetus).
Lactation	Prohibited (Women should not breastfeed).

Conditional Use

Use requires caution in patients with mild to moderate renal or hepatic impairment. Furthermore, hypokalaemia must be corrected prior to administration, and patients with certain existing cardiac arrhythmias or low baseline blood pressure require careful monitoring.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Levosimendan Richet primarily through potential pharmacodynamic reinforcement and specific population-dependent exposure constraints of its active metabolites.

---

Documented Interaction Patterns

Interacting Agent/Category	Official Documented Interaction Pattern
Other Intravenous Vasoactive Medicines	May increase the risk of hypotension; co-administration requires caution.
Isosorbide Mononitrate (Vasodilator)	Documented to cause potentiation of the orthostatic hypotensive response.
Medicines that prolong the QTc interval	Co-administration requires caution and continuous ECG monitoring.
Beta-blockers, Digoxin, Diuretics, ACE Inhibitors	The medicine can be safely administered alongside these common cardiac treatments.
Ethanol (Alcohol)	The formulation contains this excipient, which may officially alter the effects of other medicines.

---

Population-Specific Interaction Notes

Patients with mild to moderate renal or hepatic impairment may experience a more pronounced and prolonged haemodynamic effect from the active metabolites. This heightened and extended exposure necessitates a period of extended haemodynamic monitoring following infusion, as stated in regulatory prescribing information. No explicit drug-drug combinations are formally classified as contraindicated based on interaction risk.

The mechanism of action of Levosimendan Richet involves two principal cellular interactions influencing myocardial function and vascular tone.

Enhanced Strength of Heart Contraction (Calcium Sensitization)

The drug acts as a calcium sensitizer, binding to cardiac troponin C ( cTnC) within the heart muscle cells. This interaction increases the sensitivity of the contractile apparatus to the calcium ions ( Ca^2+) already present, which directly increases the force generated by the myofilaments. This mechanism allows for increased contractile force while maintaining cellular oxygen efficiency.

Modulation of Vascular Tone (Vasodilation)

The drug also functions as an opener of ATP-sensitive potassium ( K ATP) channels located in vascular smooth muscle. Activation of these channels promotes cell hyperpolarization, leading to smooth muscle relaxation and a resultant reduction in systemic vascular resistance. Furthermore, modulation of K ATP channels within heart cell mitochondria is associated with the regulation of cellular function. The combined effects result in increased stroke volume and cardiac output via augmented contractility and decreased resistance.

Levosimendan is a concentrate for solution for infusion and must be administered exclusively via the intravenous route, typically in a hospital setting with appropriate monitoring facilities. It is indicated for the short-term treatment of acutely decompensated severe chronic heart failure.

Preparation and Administration

The concentrate must be diluted prior to use. A common preparation involves diluting one 12.5 mg vial (5 mL of 2.5 mg/mL solution) in 250 mL of 5% Glucose solution to achieve a final concentration of 50 micrograms/mL. The resulting infusion solution is chemically and physically stable for 24 hours at 25°C.

Dosing Schedule and Monitoring

Treatment is typically initiated with a loading dose of 6 to 12 mu g/kg infused over 10 minutes, followed by a continuous infusion. The lower loading dose is generally recommended for patients already receiving concomitant intravenous vasodilators or inotropes.

Following the loading dose, a continuous infusion is administered, often starting at 0.1 mu g/kg/min and adjusted based on the patient's haemodynamic response. The dose may be reduced to 0.05 mu g/kg/min if an excessive response (e.g., hypotension or tachycardia) occurs, or increased up to a maximum of 0.2 mu g/kg/min if a greater effect is required. The usual recommended duration of infusion is 24 hours.

Consistent with standard critical care practice, the patient's ECG, heart rate, blood pressure, and urine output must be monitored throughout the infusion. Haemodynamic monitoring is generally recommended to continue for at least 3 days after the infusion is stopped due to the prolonged effect of active metabolites.

Research Evidence / Overview of Studies for Levosimendan Richet

Research into Levosimendan Richet has primarily focused on its short-term use in critical care situations where the heart requires immediate physiological monitoring. This evidence is derived from controlled clinical trials, including comparisons against other supportive therapies, as well as systematic reviews that combine findings from multiple studies.

---

Research Evidence for Acute Decompensated Heart Failure

Large-scale Randomized Controlled Trials (RCTs) were conducted to explore the medicine's use in severe heart failure, a condition characterized by functional limitations. Studies monitored rapid changes in heart function markers and patient-reported symptoms like shortness of breath in the short term. However, the data show patterns related to long-term patient outcomes, such as all-cause mortality and rehospitalization rates, are often mixed or uncertain across different randomized trials.

---

Evidence for Use in Low Cardiac Output Syndrome Post-Cardiac Surgery

Studies, including RCTs and observational cohorts, were conducted on patients developing Low Cardiac Output Syndrome (LCOS) after major heart surgery. Researchers examined outcomes related to systemic imbalance, such as the need for mechanical support or dialysis. The findings were mixed, and a consistent broad pattern related to major clinical outcomes was not observed across all studies that examined the general post-surgery population.

---

Research Gaps and Uncertainty

Evidence for highly specialized contexts, such as separation from the VA-ECMO life support machine, relies heavily on combining smaller, observational data. The long-term effects are not fully established, as follow-up durations in key studies were often limited beyond the initial hospital stay. Research also shows that evidence quality varies for specific sub-groups: while older adults were included in trials, data for children and those with severe kidney or liver impairment remain insufficient for drawing broad conclusions.

Common questions about Levosimendan Richet (FAQ)

Q: Is Levosimendan Richet used for all types of heart failure?

Official labeling states that this medicine is indicated for the short-term treatment of acutely decompensated severe chronic heart failure. This is a specific critical condition where the heart function has rapidly worsened.

---

Q: Are there foods or supplements that should be avoided with Levosimendan Richet?

Regulatory documents note that the formulation contains ethanol (alcohol) as an excipient. The excipient's presence is noted because it may potentially alter the effects of other medicines. There is no mention of specific foods or common supplements in the official product information.

---

Q: Are there any known interactions between Levosimendan Richet and warfarin?

In regulatory summaries, no explicit contraindications or specific major drug-drug interactions regarding warfarin are commonly described. The official interaction profile primarily focuses on other common cardiovascular medicines.

---

Q: Is it common to feel flushed or lightheaded after taking Levosimendan Richet?

According to official safety documentation, dizziness is listed as a common side effect. In addition, headache and hypotension (low blood pressure) are classified as very common effects. Hypotension can be associated with a feeling of being lightheaded.

---

Q: Does Levosimendan Richet affect liver function?

Official documents state that the medicine is contraindicated (must not be used) in patients with severe hepatic (liver) impairment. Use also requires caution in cases of mild to moderate liver impairment.

---

Q: What happens when the effects of Levosimendan Richet wear off?

The medicine is given as a 24-hour infusion, but its full haemodynamic (blood flow) effects may persist for several days after the infusion is stopped. This prolonged effect is due to the presence of its active metabolites in the body.

---

Q: Is it safe to use Levosimendan Richet if I have kidney problems?

Official product information states that use is contraindicated (must not be used) in patients with severe renal (kidney) impairment (defined as a creatinine clearance less than 30 mL/min). Use requires caution when administered to patients with mild to moderate renal impairment.

---

Q: How is Levosimendan Richet different from other heart medications?

Levosimendan Richet belongs to a unique therapeutic class known as calcium sensitizers. This mechanism is described as increasing the strength of heart contraction without significantly increasing the heart muscle’s oxygen demand. This is a key difference compared to some older heart-support medicines.

---

Q: Is Levosimendan Richet a beta-blocker?

No. The medicine is classified by the World Health Organization as a Cardiotonic agent. It is also distinguished pharmacologically as an Inodilator and calcium sensitizer, which is a different pharmacological class from beta-blockers.

---

Q: How quickly does Levosimendan Richet start working after administration?

The medicine is designed for controlled delivery via the intravenous route and has a short half-life for the parent drug. This allows for a relatively fast onset of action in the body, as noted in the pharmacokinetics summary.

---

Q: Does Levosimendan Richet stay in the body for a long time?

Yes, in effect. While the parent drug is quickly eliminated, one of its active metabolites has a prolonged elimination half-life, which can be 70 to 80 hours. This means the therapeutic effects can last for several days after the infusion is complete.

---

Q: Are there specific dosage adjustments described for elderly patients?

Official documents state that the medicine is permitted for use in elderly patients. Regulatory information indicates that no dose adjustment is required for these patients based on age alone.

---

Q: Are patients required to stay in the hospital after receiving Levosimendan Richet?

Because the medicine is administered intravenously and has prolonged haemodynamic effects after the infusion ends, patient monitoring is generally recommended to continue for at least three days after the infusion is stopped. This monitoring must be conducted in an appropriate facility.

---

Q: What is the role of the drug's active metabolite?

The active metabolite, known as OR-1896, plays a major role in the medicine’s overall effect. It is primarily responsible for the long-lasting therapeutic effects on heart function and also contributes to the vasodilation (widening of blood vessels) that is seen after the parent drug is cleared from the body.

---

Q: Does Levosimendan Richet have an impact on heart oxygen demand?

A unique aspect of its mechanism is that it enhances the strength of heart contraction without significantly increasing the heart muscle’s demand for oxygen.

---

Q: How does Levosimendan Richet affect blood flow to the kidneys?

Research evidence indicates that the medicine increases renal (kidney) blood flow and has been shown to improve the glomerular filtration rate in certain patient groups with heart failure.

---

Q: Is Levosimendan Richet used for heart conditions other than heart failure?

The primary licensed use is for severe heart failure. However, research evidence also includes studies exploring its use in patients developing Low Cardiac Output Syndrome (LCOS) after major heart surgery, which is a related critical condition.

---

Q: Does Levosimendan Richet affect potassium levels?

Yes. The official safety documentation lists Hypokalemia (a low level of potassium in the blood) as a common side effect. For this reason, official guidelines state that low potassium is generally advised to be corrected prior to receiving the medicine.

---

Q: Can Levosimendan Richet cause an allergic reaction?

Yes. Hypersensitivity (allergic reaction) to levosimendan is listed as an absolute contraindication in official regulatory documents. This classification indicates that the medicine is prohibited for use in patients known to have an allergy to it.

---

Q: Is Levosimendan Richet used before or after heart surgery?

Research evidence primarily examines the medicine’s use in patients who develop Low Cardiac Output Syndrome (LCOS) after cardiac surgery. This places its use within the perioperative clinical context (the time surrounding the operation).

---

Q: Are there different brand names for the drug Levosimendan?

Yes. The active substance is Levosimendan. It is marketed under different brand names globally, with Simdax being a widely recognized example in many regions.

---

Q: What is meant by a 'rescue therapy' in relation to Levosimendan Richet?

The medicine is indicated for use in acutely decompensated severe chronic heart failure. Official descriptions note that the purpose is to provide immediate and significant hemodynamic support to rapidly help the struggling heart.

Storage and Disposal Requirements

The storage and handling of Levosimendan concentrate must strictly follow regulatory standards to ensure product stability.

Storage Requirement	Official Condition (Unopened Concentrate)
Temperature	Store in a refrigerator (2 C to 8 C).
Freezing	Do not freeze the concentrate.
Child Safety	Keep out of the sight and reach of children.

The concentrated solution should remain in its original vial until it is prepared for infusion. After dilution, the prepared solution must be used immediately due to microbiological considerations. If necessary, the total time for preparation and infusion must not exceed 24 hours, even if the diluted solution is refrigerated.

Unused medicine, including any remaining concentrate or waste material, must be disposed of in accordance with local requirements. Disposal via wastewater or household waste is prohibited, following established pharmaceutical waste protocols.